Risks Versus Benefits of Inhaled β2-Agonists in the Management of Asthma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1992-01

AUTHORS

Brian J. Lipworth

ABSTRACT

The therapeutic goal for the treatment of asthma should be to suppress bronchial mucosal inflammation with preventive drugs such as inhaled corticosteroids, and to relieve symptoms of wheezing and breathlessness with bronchodilator drugs. The lower recommended doses of inhaled β2-agonists produce rapid effective bronchodilatation without systemic adverse effects; higher doses may produce substantial improvements in airway response which may help patients with more severe airflow obstruction. Higher doses of inhaled β2-agonists also cause dose-related systemic adverse β2 effects including tremor, tachycardia, hypokalaemia and associated electrocar-diographic sequelae. In this respect, although fenoterol appears to cause greater extrapulmonary β2-mediated adverse effects at higher doses, there is no evidence to suggest that it is any less β2 selective. There is also some evidence to suggest that use of regular inhaled β2-agonists may cause increased bronchial hyperreactivity and possibly deterioration in disease control. Patients who require such regular use should therefore be given additional anti-inflammatory therapy with inhaled corticosteroids. The recent availability of novel, longer-acting inhaled β2-agonists such as salmeterol and formoterol will also make necessary a careful reappraisal of their long term use in patients with asthma. More... »

PAGES

54-70

References to SciGraph publications

  • 1974-03. Comparison of the bronchodilator and cardiovascular actions of isoprenaline, Th 1165a, terbutaline and salbutamol in cats and isolated organ preparations in RESEARCH IN EXPERIMENTAL MEDICINE
  • 1989-05. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1991-03. Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1988-11. Effects of inhaled beclomethasone dipropionate on beta2-receptor function in the airways and adrenal responsiveness in bronchial asthma in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1989-11. Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in Patients with asthma in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1985-10. The affinity of (−)-propranolol for β1- and β1-autoreceptors of human heart in NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY
  • 1990-02. Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1967-05. Differentiation of Receptor Systems activated by Sympathomimetic Amines in NATURE
  • 1988-03. Effect of prednisolone and ketotifen onβ2-adrenoceptors in asthmatic patients receivingβ2-bronchodilators in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1991-02. A dose-ranging study to evaluate the β1-adrenoceptor selectivity of bisoprolol in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1989-05. Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta2-adrenoceptor blockade in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00002018-199207010-00007

    DOI

    http://dx.doi.org/10.2165/00002018-199207010-00007

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1053525213

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/1346963


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Inhalation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adrenergic beta-Agonists", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Asthma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Factors", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, DD1 9SY, Dundee, Scotland", 
              "id": "http://www.grid.ac/institutes/grid.416266.1", 
              "name": [
                "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, DD1 9SY, Dundee, Scotland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lipworth", 
            "givenName": "Brian J.", 
            "id": "sg:person.0733153704.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733153704.36"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf00280067", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1077253681", 
              "https://doi.org/10.1007/bf00280067"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00679788", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012896847", 
              "https://doi.org/10.1007/bf00679788"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00615220", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024174537", 
              "https://doi.org/10.1007/bf00615220"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00265986", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044254459", 
              "https://doi.org/10.1007/bf00265986"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00614551", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009739834", 
              "https://doi.org/10.1007/bf00614551"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/214597a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040361105", 
              "https://doi.org/10.1038/214597a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00562546", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1079235371", 
              "https://doi.org/10.1007/bf00562546"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00558154", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053402712", 
              "https://doi.org/10.1007/bf00558154"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00498852", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045604191", 
              "https://doi.org/10.1007/bf00498852"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01851883", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035290089", 
              "https://doi.org/10.1007/bf01851883"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00315205", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008453601", 
              "https://doi.org/10.1007/bf00315205"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1992-01", 
        "datePublishedReg": "1992-01-01", 
        "description": "The therapeutic goal for the treatment of asthma should be to suppress bronchial mucosal inflammation with preventive drugs such as inhaled corticosteroids, and to relieve symptoms of wheezing and breathlessness with bronchodilator drugs. The lower recommended doses of inhaled \u03b22-agonists produce rapid effective bronchodilatation without systemic adverse effects; higher doses may produce substantial improvements in airway response which may help patients with more severe airflow obstruction. Higher doses of inhaled \u03b22-agonists also cause dose-related systemic adverse \u03b22 effects including tremor, tachycardia, hypokalaemia and associated electrocar-diographic sequelae. In this respect, although fenoterol appears to cause greater extrapulmonary \u03b22-mediated adverse effects at higher doses, there is no evidence to suggest that it is any less \u03b22 selective. There is also some evidence to suggest that use of regular inhaled \u03b22-agonists may cause increased bronchial hyperreactivity and possibly deterioration in disease control. Patients who require such regular use should therefore be given additional anti-inflammatory therapy with inhaled corticosteroids. The recent availability of novel, longer-acting inhaled \u03b22-agonists such as salmeterol and formoterol will also make necessary a careful reappraisal of their long term use in patients with asthma.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00002018-199207010-00007", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1096281", 
            "issn": [
              "0114-5916", 
              "1179-1942"
            ], 
            "name": "Drug Safety", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "7"
          }
        ], 
        "keywords": [
          "high doses", 
          "additional anti-inflammatory therapy", 
          "bronchial mucosal inflammation", 
          "adverse effects", 
          "severe airflow obstruction", 
          "management of asthma", 
          "systemic adverse effects", 
          "anti-inflammatory therapy", 
          "treatment of asthma", 
          "Risks Versus Benefits", 
          "long-term use", 
          "effective bronchodilatation", 
          "airway responses", 
          "airflow obstruction", 
          "mucosal inflammation", 
          "bronchial hyperreactivity", 
          "preventive drugs", 
          "bronchodilator drugs", 
          "\u03b22 agonists", 
          "therapeutic goals", 
          "asthma", 
          "disease control", 
          "patients", 
          "doses", 
          "term use", 
          "regular use", 
          "corticosteroids", 
          "drugs", 
          "careful reappraisal", 
          "bronchodilatation", 
          "hypokalaemia", 
          "hyperreactivity", 
          "tachycardia", 
          "sequelae", 
          "salmeterol", 
          "formoterol", 
          "inflammation", 
          "fenoterol", 
          "obstruction", 
          "therapy", 
          "symptoms", 
          "tremor", 
          "evidence", 
          "recent availability", 
          "treatment", 
          "effect", 
          "use", 
          "substantial improvement", 
          "\u03b22", 
          "response", 
          "deterioration", 
          "management", 
          "control", 
          "benefits", 
          "improvement", 
          "selective", 
          "reappraisal", 
          "availability", 
          "goal", 
          "respect", 
          "novel"
        ], 
        "name": "Risks Versus Benefits of Inhaled \u03b22-Agonists in the Management of Asthma", 
        "pagination": "54-70", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1053525213"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00002018-199207010-00007"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "1346963"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00002018-199207010-00007", 
          "https://app.dimensions.ai/details/publication/pub.1053525213"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-10-01T06:28", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_232.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00002018-199207010-00007"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002018-199207010-00007'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002018-199207010-00007'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002018-199207010-00007'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002018-199207010-00007'


     

    This table displays all metadata directly associated to this object as RDF triples.

    190 TRIPLES      21 PREDICATES      104 URIs      84 LITERALS      12 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00002018-199207010-00007 schema:about N2e8dae1836404273941d385a445fb431
    2 N49b2d892b11f4699b62a5b5ca6e26523
    3 N64eeb0ed9a87439d9d5e34697244bbb9
    4 Nfc3d2ff38bd4419b80400e6a7aa9139e
    5 Nfd15196808d1463c87b6437eca2cd45d
    6 anzsrc-for:11
    7 anzsrc-for:1102
    8 anzsrc-for:1115
    9 schema:author N1716d7b73eee451c8f6960b232100bcb
    10 schema:citation sg:pub.10.1007/bf00265986
    11 sg:pub.10.1007/bf00280067
    12 sg:pub.10.1007/bf00315205
    13 sg:pub.10.1007/bf00498852
    14 sg:pub.10.1007/bf00558154
    15 sg:pub.10.1007/bf00562546
    16 sg:pub.10.1007/bf00614551
    17 sg:pub.10.1007/bf00615220
    18 sg:pub.10.1007/bf00679788
    19 sg:pub.10.1007/bf01851883
    20 sg:pub.10.1038/214597a0
    21 schema:datePublished 1992-01
    22 schema:datePublishedReg 1992-01-01
    23 schema:description The therapeutic goal for the treatment of asthma should be to suppress bronchial mucosal inflammation with preventive drugs such as inhaled corticosteroids, and to relieve symptoms of wheezing and breathlessness with bronchodilator drugs. The lower recommended doses of inhaled β2-agonists produce rapid effective bronchodilatation without systemic adverse effects; higher doses may produce substantial improvements in airway response which may help patients with more severe airflow obstruction. Higher doses of inhaled β2-agonists also cause dose-related systemic adverse β2 effects including tremor, tachycardia, hypokalaemia and associated electrocar-diographic sequelae. In this respect, although fenoterol appears to cause greater extrapulmonary β2-mediated adverse effects at higher doses, there is no evidence to suggest that it is any less β2 selective. There is also some evidence to suggest that use of regular inhaled β2-agonists may cause increased bronchial hyperreactivity and possibly deterioration in disease control. Patients who require such regular use should therefore be given additional anti-inflammatory therapy with inhaled corticosteroids. The recent availability of novel, longer-acting inhaled β2-agonists such as salmeterol and formoterol will also make necessary a careful reappraisal of their long term use in patients with asthma.
    24 schema:genre article
    25 schema:isAccessibleForFree false
    26 schema:isPartOf N1df9c4ee129d4a2aa9ad8be068c58b92
    27 N3657b7ba11d34cc7ae2fea4187ce77fb
    28 sg:journal.1096281
    29 schema:keywords Risks Versus Benefits
    30 additional anti-inflammatory therapy
    31 adverse effects
    32 airflow obstruction
    33 airway responses
    34 anti-inflammatory therapy
    35 asthma
    36 availability
    37 benefits
    38 bronchial hyperreactivity
    39 bronchial mucosal inflammation
    40 bronchodilatation
    41 bronchodilator drugs
    42 careful reappraisal
    43 control
    44 corticosteroids
    45 deterioration
    46 disease control
    47 doses
    48 drugs
    49 effect
    50 effective bronchodilatation
    51 evidence
    52 fenoterol
    53 formoterol
    54 goal
    55 high doses
    56 hyperreactivity
    57 hypokalaemia
    58 improvement
    59 inflammation
    60 long-term use
    61 management
    62 management of asthma
    63 mucosal inflammation
    64 novel
    65 obstruction
    66 patients
    67 preventive drugs
    68 reappraisal
    69 recent availability
    70 regular use
    71 respect
    72 response
    73 salmeterol
    74 selective
    75 sequelae
    76 severe airflow obstruction
    77 substantial improvement
    78 symptoms
    79 systemic adverse effects
    80 tachycardia
    81 term use
    82 therapeutic goals
    83 therapy
    84 treatment
    85 treatment of asthma
    86 tremor
    87 use
    88 β2
    89 β2 agonists
    90 schema:name Risks Versus Benefits of Inhaled β2-Agonists in the Management of Asthma
    91 schema:pagination 54-70
    92 schema:productId N1ed3a3df005a4bfbb1d1c2bc565cd0a7
    93 Nb48f1187fecb43cb80800f7c3066618b
    94 Ned3ef78057904cfe888783ac691a8e3d
    95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053525213
    96 https://doi.org/10.2165/00002018-199207010-00007
    97 schema:sdDatePublished 2022-10-01T06:28
    98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    99 schema:sdPublisher Nf13a1d3a4a3c4ff786140ef7a060cb05
    100 schema:url https://doi.org/10.2165/00002018-199207010-00007
    101 sgo:license sg:explorer/license/
    102 sgo:sdDataset articles
    103 rdf:type schema:ScholarlyArticle
    104 N1716d7b73eee451c8f6960b232100bcb rdf:first sg:person.0733153704.36
    105 rdf:rest rdf:nil
    106 N1df9c4ee129d4a2aa9ad8be068c58b92 schema:issueNumber 1
    107 rdf:type schema:PublicationIssue
    108 N1ed3a3df005a4bfbb1d1c2bc565cd0a7 schema:name doi
    109 schema:value 10.2165/00002018-199207010-00007
    110 rdf:type schema:PropertyValue
    111 N2e8dae1836404273941d385a445fb431 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Risk Factors
    113 rdf:type schema:DefinedTerm
    114 N3657b7ba11d34cc7ae2fea4187ce77fb schema:volumeNumber 7
    115 rdf:type schema:PublicationVolume
    116 N49b2d892b11f4699b62a5b5ca6e26523 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Administration, Inhalation
    118 rdf:type schema:DefinedTerm
    119 N64eeb0ed9a87439d9d5e34697244bbb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Adrenergic beta-Agonists
    121 rdf:type schema:DefinedTerm
    122 Nb48f1187fecb43cb80800f7c3066618b schema:name pubmed_id
    123 schema:value 1346963
    124 rdf:type schema:PropertyValue
    125 Ned3ef78057904cfe888783ac691a8e3d schema:name dimensions_id
    126 schema:value pub.1053525213
    127 rdf:type schema:PropertyValue
    128 Nf13a1d3a4a3c4ff786140ef7a060cb05 schema:name Springer Nature - SN SciGraph project
    129 rdf:type schema:Organization
    130 Nfc3d2ff38bd4419b80400e6a7aa9139e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Asthma
    132 rdf:type schema:DefinedTerm
    133 Nfd15196808d1463c87b6437eca2cd45d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Humans
    135 rdf:type schema:DefinedTerm
    136 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    137 schema:name Medical and Health Sciences
    138 rdf:type schema:DefinedTerm
    139 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    140 schema:name Cardiorespiratory Medicine and Haematology
    141 rdf:type schema:DefinedTerm
    142 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    143 schema:name Pharmacology and Pharmaceutical Sciences
    144 rdf:type schema:DefinedTerm
    145 sg:journal.1096281 schema:issn 0114-5916
    146 1179-1942
    147 schema:name Drug Safety
    148 schema:publisher Springer Nature
    149 rdf:type schema:Periodical
    150 sg:person.0733153704.36 schema:affiliation grid-institutes:grid.416266.1
    151 schema:familyName Lipworth
    152 schema:givenName Brian J.
    153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733153704.36
    154 rdf:type schema:Person
    155 sg:pub.10.1007/bf00265986 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044254459
    156 https://doi.org/10.1007/bf00265986
    157 rdf:type schema:CreativeWork
    158 sg:pub.10.1007/bf00280067 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077253681
    159 https://doi.org/10.1007/bf00280067
    160 rdf:type schema:CreativeWork
    161 sg:pub.10.1007/bf00315205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008453601
    162 https://doi.org/10.1007/bf00315205
    163 rdf:type schema:CreativeWork
    164 sg:pub.10.1007/bf00498852 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045604191
    165 https://doi.org/10.1007/bf00498852
    166 rdf:type schema:CreativeWork
    167 sg:pub.10.1007/bf00558154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053402712
    168 https://doi.org/10.1007/bf00558154
    169 rdf:type schema:CreativeWork
    170 sg:pub.10.1007/bf00562546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079235371
    171 https://doi.org/10.1007/bf00562546
    172 rdf:type schema:CreativeWork
    173 sg:pub.10.1007/bf00614551 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009739834
    174 https://doi.org/10.1007/bf00614551
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.1007/bf00615220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024174537
    177 https://doi.org/10.1007/bf00615220
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1007/bf00679788 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012896847
    180 https://doi.org/10.1007/bf00679788
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1007/bf01851883 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035290089
    183 https://doi.org/10.1007/bf01851883
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1038/214597a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040361105
    186 https://doi.org/10.1038/214597a0
    187 rdf:type schema:CreativeWork
    188 grid-institutes:grid.416266.1 schema:alternateName Department of Clinical Pharmacology, Ninewells Hospital and Medical School, DD1 9SY, Dundee, Scotland
    189 schema:name Department of Clinical Pharmacology, Ninewells Hospital and Medical School, DD1 9SY, Dundee, Scotland
    190 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...